Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Duration of anticoagulant treatment for venous thrombosis.

Current opinion in pulmonary medicine - 1 Jul 1997

Raskob G E

Abstract excerpt

Patients with deep-vein thrombosis require long-term anticoagulant treatment to prevent recurrent venous thromboembolism. Anticoagulant treatment should be continued for at least 3 months in patients with a first-episode of proximal deep-vein thrombosis. In patients with a second-episode of venou...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Factor V
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Recurrence

Share to Risk Factors

Share to Thrombophlebitis

Share to Time Factors

Source

Identifiers

PMID: 9262115
DOI: 10.1097/00063198-199707000-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-9262115-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Duration of anticoagulant treatment for venous thrombosis.PMID 9262115Read ↗

Role of thrombophilia in deciding on the duration of anticoagulation.Semantic proximity Read ↗

Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial.Semantic proximity Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.Semantic proximity Read ↗

How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation.Semantic proximity Read ↗

Management of thrombophilia.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.Semantic proximity Read ↗

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.Semantic proximity Read ↗

Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.Semantic proximity Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.